[{"address1": "2929 7th Street", "address2": "Suite 105", "city": "Berkeley", "state": "CA", "zip": "94710", "country": "United States", "phone": "510 982 6030", "website": "https://cariboubio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.", "fullTimeEmployees": 147, "companyOfficers": [{"maxAge": 1, "name": "Dr. Rachel E. Haurwitz Ph.D.", "age": 38, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1986, "fiscalYear": 2024, "totalPay": 832920, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Timothy P. Kelly M.B.A.", "age": 55, "title": "Chief Technology Officer", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 730050, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Steven B. Kanner Ph.D.", "age": 64, "title": "Chief Scientific Officer", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 668622, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Barbara G. McClung Esq., J.D.", "age": 69, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1955, "fiscalYear": 2024, "totalPay": 668622, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sriram  Ryali M.B.A.", "age": 42, "title": "Chief Financial Officer", "yearBorn": 1982, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Poon", "title": "Vice President of Operations & Information Technology", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Fischesser", "title": "Interim Principal Accounting Officer & Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amy  Figueroa C.F.A.", "title": "Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Reigin  Zawadzki", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ruhi A. Khan M.B.A.", "age": 49, "title": "Chief Business Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 573900, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 5, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.16, "open": 1.12, "dayLow": 1.09, "dayHigh": 1.16, "regularMarketPreviousClose": 1.16, "regularMarketOpen": 1.12, "regularMarketDayLow": 1.09, "regularMarketDayHigh": 1.16, "payoutRatio": 0.0, "beta": 2.438, "forwardPE": -0.55778897, "volume": 1162389, "regularMarketVolume": 1162389, "averageVolume": 1100825, "averageVolume10days": 1316370, "averageDailyVolume10Day": 1316370, "bid": 1.09, "ask": 1.13, "bidSize": 12, "askSize": 15, "marketCap": 103235104, "fiftyTwoWeekLow": 0.66, "fiftyTwoWeekHigh": 3.0, "priceToSalesTrailing12Months": 10.408863, "fiftyDayAverage": 0.92688, "twoHundredDayAverage": 1.512525, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -74355664, "profitMargins": 0.0, "floatShares": 83939443, "sharesOutstanding": 93004600, "sharesShort": 8337871, "sharesShortPriorMonth": 7631637, "sharesShortPreviousMonthDate": 1745971200, "dateShortInterest": 1748563200, "sharesPercentSharesOut": 0.089700006, "heldPercentInsiders": 0.09827, "heldPercentInstitutions": 0.53409, "shortRatio": 8.98, "shortPercentOfFloat": 0.0939, "impliedSharesOutstanding": 94608096, "bookValue": 2.336, "priceToBook": 0.47517124, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -147862000, "trailingEps": -1.62, "forwardEps": -1.99, "enterpriseToRevenue": -7.497, "enterpriseToEbitda": 0.481, "52WeekChange": -0.3657143, "SandP52WeekChange": 0.09203708, "quoteType": "EQUITY", "currentPrice": 1.11, "targetHighPrice": 32.0, "targetLowPrice": 1.0, "targetMeanPrice": 9.14286, "targetMedianPrice": 6.0, "recommendationMean": 1.66667, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 208464992, "totalCashPerShare": 2.241, "ebitda": -154644992, "totalDebt": 26224000, "quickRatio": 7.413, "currentRatio": 7.628, "totalRevenue": 9918000, "debtToEquity": 12.072, "revenuePerShare": 0.109, "returnOnAssets": -0.29212, "returnOnEquity": -0.5276, "grossProfits": -119761000, "freeCashflow": -82507872, "operatingCashflow": -137722000, "revenueGrowth": -0.031, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -18.23757, "financialCurrency": "USD", "symbol": "CRBU", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Caribou Biosciences, Inc.", "longName": "Caribou Biosciences, Inc.", "exchange": "NMS", "messageBoardId": "finmb_272189231", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1749859147, "regularMarketTime": 1749844800, "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1627047000000, "postMarketChangePercent": -2.64865, "postMarketPrice": 1.0806, "postMarketChange": -0.0294, "regularMarketChange": -0.05, "regularMarketDayRange": "1.09 - 1.16", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1100825, "fiftyTwoWeekLowChange": 0.45, "fiftyTwoWeekLowChangePercent": 0.6818181, "fiftyTwoWeekRange": "0.66 - 3.0", "fiftyTwoWeekHighChange": -1.89, "fiftyTwoWeekHighChangePercent": -0.63, "fiftyTwoWeekChangePercent": -36.57143, "earningsTimestamp": 1746734642, "earningsTimestampStart": 1746734642, "earningsTimestampEnd": 1746734642, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -1.62, "epsForward": -1.99, "epsCurrentYear": -1.64, "priceEpsCurrentYear": -0.6768293, "fiftyDayAverageChange": 0.18312001, "fiftyDayAverageChangePercent": 0.19756605, "twoHundredDayAverageChange": -0.40252495, "twoHundredDayAverageChangePercent": -0.2661278, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-07-23", "averageAnalystRating": "1.7 - Buy", "regularMarketChangePercent": -4.31034, "regularMarketPrice": 1.11, "displayName": "Caribou Biosciences", "trailingPegRatio": null, "__fetch_time": "2025-06-14"}]